{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"WRFH/Radio Free Hillsdale 101.7 FM","title":"Satya Marar: How Cheap GLP-1s Could Save Lives — AND Kill Pharma Innovation","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/a6b0e87c\"></iframe>","width":"100%","height":180,"duration":1308,"description":"The era of GLP-1 weight-loss therapies has erupted into a high-stakes showdown: major drugmakers are slashing sticker prices while regulators grapple with mounting safety and access concerns. Just recently, Wegovy and Ozempic manufacturers announced a 30% cash-price reduction for uninsured Americans. Simultaneously, three new independent reviews warn of long-term unknowns and major equity gaps in who actually benefits. With regulators scrambling to assess safety, equity, and access amid skyrocketing demand, Young Voices Contributor Satya Marar brings a crucial, nonpartisan lens from his latest article on how this policy shift reshapes innovation, affordability, and the long-term sustainability of America’s health-care system. He joins Samantha Mandel on WRFH to discuss.","thumbnail_url":"https://img.transistorcdn.com/CZyD-wr_CtIE9DPllLea0oqXShCj3ObEMIa1OFcsV48/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzMzOTg5LzE2NjI3/NTY4MzEtYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}